Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

Offer Update

29 Jul 2005 18:04

Torex Retail PLC29 July 2005 Torex Retail plc29 July 2005 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN TOREX RETAIL PLC ___________________________________________________________________________ RECOMMENDED OFFER FOR XN CHECKOUT HOLDINGS PLC Offer Unconditional as to Acceptances As at 1.00 p.m. on 29 July 2005, valid acceptances had been received in respectof 24,777,251 XN Checkout Shares (representing approximately 89.19 per cent ofXN Checkout's issued share capital). Accordingly, the Board of Torex Retail plc("Torex Retail") announces that the offer (the "Offer") made by EvolutionSecurities Limited on behalf of Torex Retail for XN Checkout Holdings PLC ("XNCheckout") has been declared unconditional as to acceptances. The Offer remains conditional upon the admission to trading on AiM of the newTorex Shares issued as consideration under the Offer ("New Torex Shares")becoming effective. Application has therefore been made for the admission of 63,107,579 New TorexShares to trading on AiM and it is expected that these New Torex Shares will beadmitted to trading on AiM and that dealings in those shares will commence on 4August 2005, when it is also expected that the Offer will become whollyunconditional. Save for the holding of Christopher Moore (Chief Executive of Torex Retail andNon-Executive Chairman of XN Checkout) of 2,580,497 XN Checkout Shares, neitherTorex Retail nor any persons deemed to be acting in concert with it for thepurposes of the Offer owned any XN Checkout Shares (or rights over such shares)on 3 June 2005 (being the last dealing day prior to the commencement of theOffer period) nor has Torex Retail nor any person deemed to be acting in concertwith it for the purposes of the Offer acquired or agreed to acquire any XNCheckout Shares (or rights over such shares) during the Offer period other thanby way of acceptances of the Offer. On 10 June 2005, Torex Retail announced that irrevocable undertakings to acceptthe Offer had been received from XN Checkout Shareholders who, in aggregate,have an interest in 10,540,085 XN Checkout Shares. Valid acceptances have beenreceived in respect of 8,500,718 of these XN Checkout Shares (representingapproximately 30.60 per cent of XN Checkout's issued share capital) and theseare included in the total above. In respect of the balance of 2,039,367 XNCheckout Shares, the acceptance form has been received duly signed, but without,as yet, sufficient supporting documentation to treat it as a valid acceptanceand therefore has not been included in the total above. The Offer will remain open until further notice. At least 14 days' notice willbe given before the Offer is closed. Terms defined in the formal Offer document dated 8 July 2005 shall, unless thecontext requires otherwise, have the same meanings in this announcement. EnquiriesTorex Retail Telephone: 01993 230 030Richard Thompson / Nigel Horn Evolution Telephone: 0207 071 4300Tim Worlledge / Jeremy Ellis This announcement is issued by Evolution which is authorised and regulated inthe United Kingdom by the Financial Services Authority. Evolution is actingexclusively for Torex Retail and is acting for no one else in connection withthe Offer and will not be responsible to anyone other than Torex Retail forproviding the protections afforded to customers of Evolution nor for providingadvice in relation to the Offer. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
30th Mar 20207:00 amRNSUpdate in relation to working capital position
20th Mar 20207:00 amRNSDirectorate Change
6th Feb 20207:15 amEQSHardman & Co Research: Tissue Regenix (TRX): Restructured to satisfy product demand
4th Feb 202011:47 amRNSResolution of Cyber Security Incident
28th Jan 202010:02 amRNSNotice of cyber security incident
22nd Jan 20207:00 amRNSTrading Update
14th Jan 20204:40 pmRNSSecond Price Monitoring Extn
14th Jan 20204:35 pmRNSPrice Monitoring Extension
21st Nov 20194:35 pmRNSPrice Monitoring Extension
18th Nov 20194:03 pmRNSDirectorate Change
14th Nov 20194:00 pmRNSHolding(s) in Company
14th Nov 20197:00 amRNSUpdated loan facility agreement with MidCap
13th Nov 20193:35 pmRNSHolding(s) in Company
13th Nov 20193:17 pmRNSHolding(s) in Company
11th Nov 20192:05 pmRNSSecond Price Monitoring Extn
11th Nov 20192:00 pmRNSPrice Monitoring Extension
11th Nov 20197:00 amRNSUpdate in relation to loan facility
17th Oct 20194:27 pmRNSHolding(s) in Company
17th Oct 20197:00 amRNSTrading Update
15th Oct 20193:27 pmRNSHolding(s) in Company
3rd Oct 20197:00 amRNSDermaPure Product Line Extension Launched
10th Sep 20197:00 amRNSUnaudited Interim Results
28th Aug 20197:00 amRNSAppointment of CFO
15th Aug 20197:00 amRNSAdditional manufacturing capacity secured
1st Aug 20197:00 amRNSDirectorate Change
8th Jul 20195:03 pmRNSHolding(s) in Company
20th Jun 20192:23 pmEQSHardman & Co Research: Tissue Regenix (TRX): Credit facilities expand cash runway to 2021
7th Jun 20192:55 pmRNSIssue of Equity and Total Voting Rights
4th Jun 20197:00 amRNSNotice of AGM
4th Jun 20197:00 amRNSSecures Credit Facilities of up to $20m
4th Jun 20197:00 amRNSAnnual Results for the year ended 31 December 2018
21st May 20197:00 amRNSCEO to return to full time duties
10th Apr 20197:20 amEQSHardman & Co Research: Tissue Regenix (TRX): Expanded GPO coverage secured
4th Apr 20197:26 amRNSExpands US GPO coverage for DermaPure
18th Feb 20197:00 amRNSChange of Adviser
6th Feb 201911:05 amRNSSecond Price Monitoring Extn
6th Feb 201911:00 amRNSPrice Monitoring Extension
4th Feb 20197:00 amRNSTrading Update
17th Dec 201811:56 amEQSHardman & Co Research: Tissue Regenix (TRX): 2018 in review: foundations laid for osteobiologics
6th Dec 20187:00 amRNSInterim Management Change
13th Nov 20187:00 amRNSPan European distribution agreement with Arthrex
29th Oct 20187:00 amRNSGareth Jones commences position as CFO
14th Sep 20187:16 amEQSHardman & Co Research: Tissue Regenix (TRX): Strategy delivering growth above expectations
3rd Sep 20187:00 amRNSUnaudited Interim Results
2nd Aug 201810:10 amEQSHardman & Co Research: Tissue Regenix (TRX): 1H'18 preview: organic plus inorganic growth
2nd Aug 20187:00 amRNSNotice of Interim Results
4th Jul 20187:00 amRNSAppointment of CFO
25th Jun 20187:00 amRNSHTA License granted and UK distribution Agreement
21st Jun 20187:10 amRNSTRX BioSurgery wins GPO Supplier Horizon Award
18th Jun 20187:00 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.